Summary: Dystonia is a prevalent neurological disorder characterized by abnormal co-contractions of antagonistic muscle groups that produce twisting movements and abnormal postures. The disorder may be inherited, arise sporadically, or result from brain insult. Dystonia is a heterogeneous disorder because patients may exhibit focal or generalized symptoms associated with abnormalities in many brain regions including basal ganglia and cerebellum. Elucidating the pathogenic mechanisms underlying dystonia has therefore been challenging. Animal models of dystonia exhibit similar heterogeneity and are useful for understanding pathogenesis. The neurochemical and neurophysiological abnormalities in rodents with idiopathic generalized dystonia suggest that dysfunctional output from basal ganglia, cerebellum, or from multiple systems is the cause of motor dysfunction. Findings from drug-or toxininduced dystonia in rodents and nonhuman primates mirror the genetic models. The parallels between dystonia in humans and animals suggest that the models will continue to prove useful in determining pathogenesis. Furthermore, detailed characterization of the existing models of dystonia and the development of new models hold promise for the identification of novel therapeutics.
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Dystonia is the third most common movement disorder behind essential tremor and Parkinson disease. Dystonia is characterized by involuntary twisting movements and abnormal postures, which are caused by simultaneous contractions of opposing muscle groups. Dystonia can be classified in terms of etiology; it may be inherited or arise sporadically (primary cases), or follow brain trauma or insult (secondary cases). However, it is estimated that approximately two thirds of all dystonia cases are not associated with identifiable pathology and are therefore deemed idiopathic. Dystonia may also be classified by the distribution of affected muscle groups. Focal or segmental forms of the disorder involve a small number of muscles, such as those of the hand in writer's cramp or of the neck in torticollis. In contrast, generalized dystonia, the focus of this review, is characterized by involvement of muscles throughout the body as observed in DYT1 (early onset torsion) dystonia. The etiological and phenotypic diversity of disorders classified as dystonia underscores its heterogeneity.
Movement disorders are often attributed to dysfunction of the basal ganglia (e.g., chorea and bradykinesia) or the cerebellum (e.g., ataxia and tremor). In particular, dystonia has traditionally been considered to be a disorder of the basal ganglia because patients with secondary dystonia commonly exhibit lesions within basal ganglia structures, including caudate, putamen, globus pallidus, and thalamus 1 ; functional imaging demonstrates that these types of lesions are associated with metabolic abnormalities within basal ganglia and premotor cortex. Further, DOPA-responsive dystonia almost certainly results from basal ganglia dysfunction. [2] [3] [4] However, substantial evidence also implicates cerebellar dysfunction in cases of both primary and secondary dystonia. Several studies reveal hypermetabolic signals within premotor cortex and cerebellum associated with primary dystonias, such as hemidystonia, exercise-induced paroxysmal dystonia, and DYT1 dystonia. 4 -7 Moreover, patients with secondary cervical dystonia most commonly exhibit lesions within cerebellum or its afferents. 8 Thus, these clinicopathologic correlations suggest dysfunction of the basal ganglia, cerebellum, or both regions as potential sources of dystonia in humans.
Animal models are essential to investigate the neurobiological basis of disease pathogenesis because idiopathic dystonias are functional disorders. Several models of generalized dystonia exist, including those exhibiting dysfunction of the basal ganglia, cerebellum, or both systems. Dystonia in animals may result from inherited mutations (primary) or be experimentally introduced (secondary). Hence, animal models of dystonia exhibit a heterogeneity that parallels the human disorder. Given the inherent limits associated with conducting experiments in patients, spontaneous and derived animal models are valuable tools for discerning the neuroanatomical, biochemical, and physiological basis of dystonia, and for testing potential therapeutics.
ANIMAL MODELS IMPLICATING BASAL GANGLIA DYSFUNCTION
The dt sz hamster Motor dysfunction. The dt sz motor disorder was identified within an inbred line of Syrian hamsters and originally described as a recessively inherited epileptic disorder. 9 However, further analysis of the dt sz hamster phenotype reveals that it bears a close resemblance to generalized paroxysmal dystonia in humans; stress-induced dt sz hamster attacks of dystonia can last for hours and vary in severity, progressing from the head to the extremities. 10, 11 Generally, attacks begin with ear flattening and facial contortions, followed by stiffening of the hind limbs, gait abnormalities and frequent falling, and culminating with limb hyperextension and severe truncal torsion and flexion. 10 Attacks in dt sz hamsters are age dependent because they are observable after the second week, peak in severity between the fourth and sixth week, and disappear sometime after the eighth week of life. 12 Although dt sz hamsters lose the susceptibility to attack during pubescence, male or female gonadectomy does not preclude remission. 13 In fact, the dt sz phenotype is not entirely transient because late-term pregnant and nursing female dt sz hamsters may exhibit the dystonic attacks. 9, 13 Thus, dystonia in adult dt sz hamsters is likely modified but not determined by hormonal fluctuations.
Neuropathology. Upon gross histological examination, the dt sz hamster brain appears relatively normal. 14 However, a reduction in parvalbumin immunoreactivity is observed throughout the dt sz hamster striatum, suggesting a marked deficit in the number of GABAergic interneurons and implicating the basal ganglia as the source of dystonic attacks. 15 Pharmacological findings further support the notion of aberrant basal ganglia GABAergic neurotransmission as a factor in the dt sz hamster disease pathogenesis. Systemic administration or intrastriatal injection of agents that increase GABAergic transmission either ameliorate or block dt sz attacks. 10, 16, 17 In contrast, systemic or local application of GABA receptor antagonists worsens the dystonia. 10, 16, 17 The improvement observed with drugs that promote GABA release likely occurs by offsetting the significant deficit of GABAergic striatal interneurons, which predicts disinhibition of striatal efferents. 15 These defects in GABAergic regulation within the striatum suggest the dt sz disorder may be pathogenically related to some forms of idiopathic paroxysmal dyskinesia in humans because dystonia in mutant hamsters and patients responds to similar pharmacological treatments, such as systemic administration of benzodiazepines. 10, 17, 18 Mutant hamsters also exhibit abnormal striatal dopamine regulation. Although interictal levels are normal, attacks of dystonia are associated with transient but significant increases in striatal dopamine overflow. 19 Furthermore, intrastriatal coadministration of D1 and D2 dopamine receptor antagonists prevents dt sz attacks, suggesting that increased dopamine overflow is necessary for the expression of dystonic symptoms.
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Pathophysiology. The dt sz hamster basal ganglia exhibit several neurophysiological abnormalities. Baseline EEG recordings from asymptomatic animals reveal highly irregular patterns of electrical activity within caudate, putamen, and globus pallidus. 21 Furthermore, field and single unit recordings of evoked and spontaneous activity within the dt sz striatum suggest these irregularities may stem from significant increases in corticostriatal and striatopallidal excitability. 22, 23 These abnormalities appear to have profound effects within the entopeduncular nucleus, which is the equivalent of the internal segment of the globus pallidus in humans. In the absence of dystonic attacks, recordings of single unit activity demonstrate significant reductions in spontaneous discharge rate and irregular burst morphology within the dt sz entopeduncular nucleus, suggesting physiological abnormalities observed within striatum result in increased entopeduncular inhibition. 15, 24 Interestingly, entopeduncular physiological abnormalities are age dependent and are detectable only in attack-prone animals. 12, 24 Thus, the aberrant neurophysiological activity detected within the dt sz basal ganglia point to dysfunctional output from the entopeduncolothalamic pathway in the generation of dystonia.
Dystonia induced by 3-nitropropionic acid
Clinical studies. Several outbreaks of noninflammatory encephalopathy have occurred in humans as a result of ingesting moldy sugarcane. The contaminant, arthrinium fungus, produces 3-nitropropionic acid (3-NPA), a potent neurotoxin that interferes with mitochondrial respiration. 25 Although acute 3-NPA poisoning is characterized by severe gastrointestinal distress, CNS symptoms such as convulsions or coma commonly follow. 26 Shortly after consciousness is regained, up to 25% of adolescent patients develop segmental or generalized dystonia, which may be chronic or paroxysmal. 26, 27 Although the distribution and character of dystonia varies between patients, cranial imaging reveals a common neuropathology: acquired lesions of the basal ganglia. In particular, computed tomography scan and magnetic resonance imaging (MRI) demonstrate that cases of secondary dystonia after 3-NPA ingestion are associated with consistent bilateral hypodensity within striatum and globus pallidus. 26, 27 Subsequently, 3-NPA was administered to nonhuman species to establish an inducible model for dystonia.
Experimental studies. Peripheral administration of 3-NPA to rodents results in nearly selective lesions of striatum, 25, 28, 29 and is associated with a motor disorder that closely resembles 3-NPA toxicity in humans. In mouse and rat, delayed onset dystonia is characterized by truncal and limb dystonia, the severity of which correlates with the size of striatal lesions. 29, 30 Furthermore, as in humans, the response of rats to 3-NPA toxicity is age dependent, whereby younger animals are more susceptible to acquiring the dystonia. 25 Nonhuman primates also exhibit late-onset dystonia after administration of 3-NPA. Dystonic movements begin several weeks after cessation of 3-NPA treatment and generally progress until symptoms become generalized. 31, 32 Here again, MRI indicates the dystonia is associated with lesions of caudate and putamen after either subacute or chronic doses. [31] [32] [33] Moreover, as noted in humans and rodents, the severity of dystonia observed in nonhuman primates is consistent with the degree of striatal damage induced by 3-NPA toxicity. 31 Histological examination of striatal damage induced by 3-NPA in both rodents and nonhuman primates indicates a major loss of striatal projection neurons, 25, 29, 33 coupled with increases in striatal dopamine, suggesting a reduction in striatonigral inhibition. 34 Thus, 3-NPA-induced striatal lesions predict dysfunctional basal ganglia output is the cause of dystonia.
Dystonia induced by chronic dopamine therapy
Nonhuman primate studies. Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a selective loss of striatal dopaminergic innervation from substantia nigra. Patients with PD often exhibit tremor, bradykinesia, and shuffled gait. In humans and nonhuman primates, the mitochondrial complex II inhibitor with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces selective lesions of dopamine-containing cells within the substantia nigra, replicating the symptoms of PD. [35] [36] [37] Consequently, the MPTP-treated nonhuman primate is the most commonly used primate model of PD.
Dopamine replacement therapy through chronic administration of the dopamine precursor levodopa (L-DOPA) or of dopamine receptor agonists remains the most effective treatment for PD. However, long-term dopamine replacement in PD has major drawbacks because dyskinesia with features of dystonia is a common side effect in both PD patients and MPTP-treated nonhuman primates, and 6-OHDA-treated rodents. 38 -43 Dyskinesia with dystonia also occurs in healthy nonhuman primates following chronic L-DOPA administration alone. 44 In all cases, the severity of dyskinesia correlates with the amount of striatal damage preceding treatment as well as duration and intensity of drug administration. 39, 40, 44 Functional imaging and metabolic mapping studies suggest dyskinesia after chronic dopamine replacement therapy is associated with abnormal activity within basal ganglia, resulting in dysfunctional thalamocortical input.
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Comment on basal ganglia dysfunction in dystonia
Animal models of generalized dystonia implicating dysfunctional basal ganglia output are associated with significant pathology within striatum. The dt sz basal ganglia exhibit widespread electrophysiological abnormalities, possibly due to deficits in striatal GABAergic transmission, predicting decreased output from the entopeduncolothalamic pathway. However, the physiological evidence from studies of human dystonia is not as clear. Whereas pallidal discharge rates are reduced in patients with dystonia, suggesting that neostriatal activity is increased, 48 -51 dual recordings of globus pallidus and putamen in dystonic patients do not support this conclusion because a reduction in discharge rates is observed in both structures. 48 The dystonia associated with 3-NPA toxicity and with long-term dopamine replacement therapy in animal models and patients suggests a role for this neurotransmitter in the disorder. Whereas dystonia in dt sz hamsters and 3-NPA treated animals is associated with a significant increase in striatal dopamine overflow, striatal dopamine deficiency can also result in dystonia as observed in DOPA-responsive dystonia. 20, [52] [53] [54] Although the exact pathogenic mechanisms are not clear, primary and secondary pathological defects in basal ganglia output likely result in aberrant thalamocortical input and disorganized motor processing.
ANIMAL MODELS IMPLICATING CEREBELLAR DYSFUNCTION
The dt rat Motor dysfunction. The recessively inherited dt rat motor disorder was first observed within a colony of Sprague Dawley breeders. 55, 56 Whereas motor dysfunction is undetectable in neonates, dt rats develop generalized dystonia approximately 10 days after birth, with twisting movements of the neck, paddling motions of the limbs and postural instability. 55, 56 After onset of the dt motor phenotype, symptom severity and distribution progress rapidly; dt rats display fore-and hindlimb selfclasping, truncal flexion, and sustained axial twisting movements (FIG. 1A) . 55, 56 As in human generalized dystonia, motor dysfunction occurs only in waking dt rats and subsides during rest.
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Neuropathology. Despite the early onset of severe symptoms, no obvious gross neuroanatomical abnormalities are apparent except for an overall reduction in dt rat brain mass. 55 This reduction, which is observed in older dystonic animals, is likely due to feeding deficits rather than a degenerative process, 55 because histological examination of striatum, cerebellum, and deep cerebellar nuclei reveals no significant evidence of cells loss within the dt rat brain. 55, [57] [58] [59] However, cytological studies demonstrate that Purkinje cell soma are significantly smaller in dt rat brain, implicating the cerebellum in the motor phenotype. 58, 60 Although abnormal metabolic activity is detected throughout the dt rat motor system, including striatum, 61 there is little evidence to suggest that the basal ganglia are specifically affected. 55, 57, 62 However, several neurochemical abnormalities are observed within cerebellum. First, the concentration of norepinephrine is significantly increased within the dt rat cerebellum 55 but does not likely factor in the dystonia. 58, 63 Next, both GABA synthesis and concentration are significantly elevated in dt rat Purkinje cells, but not in basal ganglia. 64 -66 In contrast, cells of the deep cerebellar nuclei (DCN), where Purkinje cell axons terminate, exhibit a substantial reduction in GAD activity and GABA receptor density. 62, 65 Because the development of the GABAergic abnormalities parallels the progression of the disease, 64, 67 and because diazepam provides relief, 55, 64 GABAergic dysregulation likely contributes to the expression of the dystonia.
The biochemical perturbations observed within dt rat cerebellum may result from abnormal Purkinje cell innervation by climbing afferents from the inferior olive (IO). Dystonic rats are insensitive to the tremorogenic effects of harmaline, which potentiates climbing fiber input. 60 In contrast, dt rats are hypersensitive to tremorogenic effects induced by the serotonergic agonist quipazine, which also stimulates IO activity. 68 Serotonergic regulation appears normal elsewhere in dt rat brain, 62, 63 suggesting defects specific to the olivocerebellar pathway are associated with the dystonia.
Pathophysiology. The olivocerbellar network is also the site of neurophysiological irregularities including abnormal spontaneous activity from the dt rat IO, Purkinje cell layer, and DCN. 59, 69, 70 Single unit recordings from dt rat Purkinje neurons reveal a reduced rate of complex spiking and abnormal patterns of simple spike bursting. 71 In addition, the increase in complex spike activity normally observed in response to harmaline is absent in dt rat Purkinje cells, 60, 71 which is consistent with the failure of harmaline to induce tremor in these animals. Neurons within the dt rat lateral and interpositus DCN display increased rhythmic bursting, with the most severe alterations in patterned activity detected in older animals with advanced dystonia. 72 Hyperpolarizing current injections or artificial stimulation of Purkinje cell input exerts similar effects in preparations from normal brain, 73 suggesting that rhythmic bursting within the dt rat DCN is a consequence of aberrant Purkinje cell input. Taken together, the data implicate defective climbing fiber innervation of Purkinje cells and predict dysfunctional output from cerebellum. Perhaps the most compelling evidence for the involvement of the cerebellum is that either removal of the cerebellum or lesions of the DCN alleviate symptoms in dt rats, indicating cerebellar output is necessary for dystonia.
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The Ca v 2.1 calcium channel mouse mutants Human and mouse mutations. Ca v 2.1 (P/Q-type) calcium channels regulate neurotransmitter release and neuronal firing patterns throughout the brain. However, these voltage-gated channels are expressed abundantly within Purkinje cells of the cerebellum, where they are located presynaptically on axon terminals 76 and postsynaptically on dendrites and soma. 77 Several human neurological diseases characterized by cerebellar dysfunction including episodic ataxia type 2, familial hemiplegic migraine, and spinocerebellar ataxia type 6, result from mutations within the CACNA1A gene, 78, 79 which en-
FIG. 1. Typical dystonic postures observed in dt rats (A), tottering mice (B), and kainate-induced dystonia (C).
codes the pore-forming ␣ 1 2.1 subunit of Ca v 2.1 calcium channels. In addition to the signs for which each disorder was named, patients may also suffer from dystonia. 80 -86 Mice bearing mutations within the Cacna1a gene are models of dystonia arising from cerebellar dysfunction; dystonia is a prominent feature of the tottering 87 and leaner (as observed by authors) mouse motor phenotypes. Both Cacna1a mutations associated with the tottering and leaner motor disorders, Cacna1a tg and Cacna1a tg-la , arose spontaneously and result in abnormal Ca v 2.1 calcium channel function. 88 -90 Moreover, mice carrying targeted disruptions of Cacna1a, which eliminate Ca v 2.1 currents entirely, also exhibit a motor disorder reminiscent of generalized dystonia in humans. 91, 92 Motor dysfunction. Tottering is a recessively inherited motor disorder where mice experience highly stereotyped paroxysmal episodes of motor dysfunction, which last 20 -60 min and are precipitated by stress, caffeine, and ethanol. 93 Attacks in tottering mice usually begin with hindlimb posturing, then spread and become generalized to include truncal and neck flexion, forelimb posturing and facial contortion (FIG. 1B) . [93] [94] [95] At the most advanced stages of attack, tottering mice typically assume prolonged twisting postures involving the entire body, including the ears, eyes and jaw. 93, 94 Between attacks, tottering exhibit a mild, but noticeable ataxia. Although the tottering mouse phenotype was initially described as a motor seizure disorder, 96 no epileptiform activity is associated with the motor dysfunction, 95, 96 and the sustained and asynchronous movements observed during attacks more closely resemble those of paroxysmal dystonia in humans.
The motor disorders of leaner mice and the Ca v 2.1 null mutants are recessively inherited and are chronic. Beginning approximately 2-3 weeks after birth, progressive and debilitating dystonia develops, which in weanlings causes death indirectly by inhibiting feeding. 91, 92, 97, 98 Whereas the leaner disorder was originally classified as an ataxic disorder, dystonic extension of the limbs on one side of the body actually causes these mice to lean and ultimately fall (as observed by authors). Furthermore, the motor dysfunction in leaner is widespread with involvement of the tongue and jaw muscles, suggesting that it is a model of generalized dystonia rather than ataxia. The Ca v 2.1 null mutant phenotype is very similar to the leaner mouse, but more severe.
Neuropathology. Although neuronal degeneration is not observed in tottering mice, 94, 96 total cerebellar volume is significantly less than in wild-type mice. 99 A reduction in Purkinje cell size may account for the atrophic tottering mouse cerebellum; abnormalities in dendritic and axonal morphology also suggest altered connectivity within cerebellar circuitry. 98 -100 In contrast, widespread cerebellar atrophy occurs in leaner mice and the Ca v 2.1 null mutants with progressive degeneration of granule, golgi, and Purkinje neurons. 91, 92, 101, 102 In fact, by 1 year of age, only about 20% of the original population of Purkinje cells remains in leaner mice. 102 Additionally, Purkinje cells in both tottering and leaner mice exhibit ectopic expression of tyrosine hydroxylase [103] [104] [105] that is likely due to an increase in Ca v 1.2 (L-type) channel expression resulting from the reduction in Ca v 2.1 activity. 106 In general, the neuropathology observed in these mice points to dysfunctional Purkinje cells without obvious striatal dysfunction.
Pathophysiology. Tottering mouse Purkinje cells exhibit an approximate 40% reduction in Ca v 2.1 calcium current density. 88 The reduced Ca v 2.1 current density in tottering triggers compensatory mechanisms to maintain calcium homeostasis, such as the upregulation of Ca v 1.2 channels. 87 Indeed, these secondary effects may contribute to the dystonia because blockers of Ca v 1.2 activity prevent dystonic attacks in tottering mice, whereas the Ca v 1.2 channel activator Bay K8644 induces stereotypic episodes in tottering mice. 87 Additionally, an apparent shift to reliance on Ca v 2.2 (N-type) channels for neurotransmission 107, 108 may underlie the reduced electrical coupling between granule and Purkinje cells synapses and the increased sensitivity to modulation by G proteins detected in tottering cerebellum. 109, 110 The reduction and absence of Ca v 2.1 currents in leaner mice and the null mutants, respectively, 89 -92,105 also trigger compensatory changes in calcium handling. In mice without Ca v 2.1 currents, increased expression of both Ca v 1.2 and Ca v 2.2 channels is observed. 91, 92 Furthermore, studies of leaner Purkinje cells demonstrate that diminished Ca v 2.1 activity is associated with decreased expression of calcium-binding proteins, lessening the ability to properly buffer intracellular calcium. 111 Whereas mouse mutants with reduced or abolished Ca v 2.1 currents exhibit significant cerebellar pathophysiology, the exact mechanisms of dystonia are not clear. In tottering mice, dystonia is associated with activation c-fos expression within the entire olivocerebellar network and its efferent targets, but not within basal ganglia. 112 Moreover, genetic, chemical or surgical lesions that partially or completely eliminate cerebellar output alleviate dystonic attacks in tottering mice, 113, 114 suggesting that the cerebellum is necessary for the expression of dystonia.
Dystonia induced by kainate
Microinjection studies. Low-dose microinjections of the glutamate receptor agonist kainate into the cerebellar vermis induce dystonia in normal mice. 115 Approximately 10 -20 min after injection, abnormal movements begin with the hindlimbs, but shortly thereafter symptoms become more generalized to include the trunk and forelimbs (FIG. 1C) . Similar to dystonia in tottering, kainate-induced dystonia in normal mice is associated with increased c-fos expression within cerebellum. 112, 115 Only cerebellar injection of glutamatergic agonists but not antagonists results in dystonia, clearly demonstrating involvement of kainate or AMPA receptor activation 115 Microinjection of kainate into basal ganglia does not induce motor dysfunction, nor does it induce dystonia when injected into the cerebella of mice lacking Purkinje cells, indicating that output from cerebellum is necessary for expression of the dystonia.
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Comment on cerebellar dysfunction in dystonia
Models of idiopathic and secondary generalized dystonia in mouse and rat implicate the cerebellum in this movement disorder. Dystonia is a movement disorder characterized by disrupted timing and coordination of antagonistic muscle contractions, and one that has been traditionally viewed as being associated with dysfunctional basal ganglia output. Neurological disorders originating from cerebellum, such as ataxia, are normally associated with loss of function. However, evidence from clinical studies implicates abnormal cerebellar activity in dystonia, which can be viewed as a gain of function lesion similar to epilepsy in the cerebral cortex. Along with the expected metabolic increases in the caudate, lentiform nuclei, and supplementary motor areas, positron emission tomography (PET) detects hypermetabolism within the cerebella of patients suffering from DYT1, an early-onset idiopathic torsion dystonia. 116, 117 Similarly, in acquired hemisdystonia, which affects one side of the body, PET reveals hypermetabolism within ipsilateral cerebellum and several contralateral cortical motor areas. 4 Moreover, patients with exercise-induced paroxysmal dystonia exhibit increased cerebellar perfusion and reduced cortical and basal ganglia perfusion during motor attacks. 118 Taken together, findings from animal and clinical studies demonstrate that dysfunctional cerebellar output is sufficient for the expression of generalized dystonia.
SUMMARY AND CONCLUSIONS
Dystonia is a prevalent movement disorder in humans, generally characterized by the simultaneous contraction of opposing muscle groups. The circumstances of dystonia are variable, manifesting in paroxysmal or chronic symptoms with focal or generalized patterns of distribution. Whereas initial clinical studies implicated pathology within basal ganglia as the principal source of idiopathic and acquired dystonias, substantial evidence identifies cerebellar dysfunction as another common cause of the disorder.
Clearly, the heterogeneity exhibited by human dystonia is represented in animal models of the disorder. Several demonstrate that dysfunctional output from the basal ganglia can result in dystonia. In these models, abnormal nigrostriatal dopaminergic neurotransmission 19, 20, 39, 40, 44 accompanied by neurophysiological irregularities predict disorganized thalamocortical signaling that may drive the dystonia. 22, 24, 119 In contrast, the models of dystonia implicating the cerebellum predict abnormal cerebellar signaling, including Purkinje cells and deep cerebellar nuclei, with involvement of the entire olivocerebellar system. 56, 59, 115 Moreover, selectively eliminating cerebellar output in these cases blocks the dystonia. 74, 75, 113, 114 Considering that both systems serve to modulate movement, the notion that simultaneous dysfunction of basal ganglia and cerebellum may be involved in different manifestations of dystonia is not unreasonable.
However, it is unlikely that the pathogenesis in all dystonias is simply due to either basal ganglia or cerebellar dysfunction. Dystonia may be associated with neuronal dysfunction that is widespread. Dystonia musculorum is a mouse motor disease resembling generalized dystonia in humans. The disorder results from mutations of the Bpag1 gene, which encodes a protein important in the cytoskeletal organization of all neurons. 120, 121 As a consequence, mice with dystonia musculorum exhibit lesions within several brain regions, including basal ganglia, cerebellum and sensory neurons. 122, 123 The dystonia evoked by Ca v 1.2 (L-type) calcium channel activation also implicates widespread neuronal dysfunction. In normal animals, administration of Bay K 8644 or FPL 64179, both L-type calcium channel agonists, induces generalized dystonia that is associated with extensive neuronal activation throughout brain, including striatum, cerebellum, hippocampus, and cortex. 124, 125 Elucidating the pathophysiology that ultimately generates the dystonia in such models may be particularly challenging.
The evidence emerging from both clinical and animal studies demonstrates that dystonia may be associated with dysfunction of broad networks or with defects in the basic components of motor control. Moreover, animal models clearly support the idea that dystonia may involve pathology within single or multiple motor pathways. Given the clinical heterogeneity of the disorder, these implications are not surprising. That the animal models of dystonia mirror the human findings is promising, but the complexity of the disorder in both cases suggests that a single defining mechanism of pathogenesis is unlikely. The development of therapeutics may therefore necessitate novel strategies targeting broad categories of dystonia. Animal models of dystonia hold potential for such an approach whereby therapeutics effective in several different models will provide strong evidence for clinical efficacy.
